GSK plc vs Norwegian Cruise Line Holdings Ltd — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Norwegian Cruise Line Holdings Ltd trades at $15.57 (market cap $7.11B). The key difference: GSK plc is far larger — about 12.9× Norwegian Cruise Line Holdings Ltd's market cap, and GSK plc pays a 3.9% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| GSK | NCLH | |
|---|---|---|
Market Cap | $91.88B | $7.11B |
Volume | 7,730,529 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $25.02 |
52-Week Low | $43.24 | $14.12 |
Typical Hold Time | 93 Days | 68 Days |
Enterprise Value | $111.88B | $21.93B |
Dividend Yield | 3.9% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Norwegian Cruise Line Holdings (NCLH) trades at $15.49, up 2.92% with bullish technical signals and strong earnings beats. The company shows improving fundamentals with $9.83B revenue in 2025 and net income of $423M, while maintaining attractive valuation metrics including a 9.39 P/E ratio. Recent news highlights management's expectation for Q3 2026 results to exceed guidance, driven by better-than-expected revenue performance.
NCLH presents a compelling investment case with analyst consensus pointing to 35% upside to the $20.86 price target. However, investors face risks from persistent yield pressure, high debt levels ($11.78B long-term debt), and competitive Caribbean pricing. The stock's outlook remains positive given consecutive earnings beats and management's pricing strategies to stabilize performance through 2027.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →